Nobivac Canine 3-DAPv (Canada)This page contains information on Nobivac Canine 3-DAPv for veterinary use.
The information provided typically includes the following:
- Nobivac Canine 3-DAPv Indications
- Warnings and cautions for Nobivac Canine 3-DAPv
- Direction and dosage information for Nobivac Canine 3-DAPv
Nobivac Canine 3-DAPvThis treatment applies to the following species:
CANINE DISTEMPER-ADENOVIRUS TYPE 2-PARVOVIRUS VACCINE
Modified Live Virus
FOR ANIMAL USE ONLY
IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.
Nobivac Canine 3-DAPv Indications
This product has been shown to be effective for vaccination of healthy dogs 7 weeks of age or older against canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease) and canine parvovirus. Duration of Immunity is at least 3 years. To review efficacy and safety data, go to productdata.aphis.usda.gov.
Dosage and AdministrationTransfer contents of the sterile diluent vial to the Nobivac® Canine 3-DAPv vial aseptically. Mix gently until dissolved. Inject one dose (1mL) subcutaneously. The initial dose may be given at 7 weeks of age or older. Repeat dose 3 to 4 weeks later. Two doses are required for primary immunization.
The presence of maternal antibodies is known to interfere with the development of active immunity in dogs and additional boosters will be required in most young animals. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
● Store at 2° - 8°C (35°-46°F).
● Do not freeze.
● Use new, non-chemically sterilized needles and syringes.
● Do not mix with other products, except as specified on the label.
● Inactivate unused contents before disposal.
● In case of human exposure, contact a physician.
● Contains gentamicin as a preservative.
● Vaccinate only healthy, non-parasitized dogs.
● Do not vaccinate pregnant bitches.
● Occasionally, transient corneal opacity may occur following the administration of this product.
● The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
● The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch’s titer and quantity of colostral antibodies absorbed by the puppy.
Intervet Inc. d/b/a Merck Animal Health
Omaha, NE 68103 USA
VLN 165A/PCN 1331.20
1 800 224-5318 (USA)
1 866 683-7838 (CAN)
For patent information:
Intervet Canada Corp.
16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
|Fax:||Toll-free 888-498-4444; local 514-428-7014|
Copyright © 2023 Animalytix LLC. Updated: 2023-05-30